Find Research Projects

Search results

• A Phase 2/3, Multicenter, Randomized, Double-blind

  Bellin, M. D. & Dunn, T. B.

  DOMPE S.P.A

  1/1/14 → 12/31/17

  Project: Research project

• A Phase 2/3, Double-Blind, Placebo-Controlled, Two-Part

  Matas, A. J.

  Astellas Pharma US, Inc.

  12/1/11 → 1/31/13

  Project: Research project

• A Phase 2, single-arm, open-label study to evaluate the safety and efficacy of MGTA-456 in patients with sickle cell disease (SCD) undergoing hematopoietic stem cell transplantation (HSCT)

  Smith, A. R.

  MEDPACE, INC.

  1/1/20 → 12/31/20

  Project: Research project

• A Phase 2, Single-arm, Open-label, Study to Evaluate

  Orchard, P. J. & Lund, T. C.

  MAGENTA THERAPEUTICS

  1/15/18 → 1/14/21

  Project: Research project

• A Phase 2, Sequential, Ascending Dose Study to Character

  Kim, H. J.

  Celgene Corporation

  4/13/10 → 4/12/15

  Project: Research project

• A Phase 2, Randomized Study to Assess the Safety and Ant

  Green, J. S.

  ViroPharma Incorporated

  8/1/12 → 7/31/15

  Project: Research project

• A Phase 2, Randomized Prospective, Double-Masked, Vehicle-Controlled Study to assess the Efficacy andSafety of Nexagon (NEXAGON) Applied Topically in Subjects with Corneal Persistent Epithelial Defects(PED) Resulting from Severe Ocular Chemical and/or

  Hou, J. H.

  OCUNEXUS THERAPEUTICS, INC

  7/15/19 → 7/31/24

  Project: Research project

• A Phase 2, Randomized, Open-label Study of Nivolumab or Nivolumab/BMS-986205 Alone or Combinedwith Intravesical BCG in Participants with BCG-Unresponsive, High-Risk,Non-Muscle Invasive BladderCancer

  Zabell, J. R. & Konety, B. R.

  BRISTOL-MYERS SQUIBB COMPANY

  7/5/18 → 7/30/23

  Project: Research project

• A Phase 2, Randomized, Multicenter Study to Evaluate the Efficacy and Safety of KD025 in Subjects with Chronic Graft Versus Host Disease (cGVHD) After At Least 2 Prior Lines of Systemic Therapy

  Arora, M.

  KADMON CORPORATION, LLC

  9/11/18 → 9/30/23

  Project: Research project

• A Phase 2, Randomized, Multicenter, Placebo-Controlled,

  Lake, J. R.

  EISAI MEDICAL RESEARCH INC.

  12/22/11 → 8/3/12

  Project: Research project

• A Phase 2, Randomized, Efficacy and Safety Study of Impr

  Jha, G.

  BIOTHERA

  10/27/09 → 10/31/12

  Project: Research project

• A Phase 2, Randomized, Double-blind Study to Evaluate the Efficacy and Safety of VX-561 in Subjects Aged 18 Years and Older with Cystic Fibrosis

  Dunitz, J. M.

  Vertex Pharmaceuticals Incorporated

  3/21/19 → 1/1/21

  Project: Research project

• A Phase 2, Randomized, Double-blind Study to Evaluate the Efficacy and Safety of VX-561 in Subjects aged 18 Years and Olderwith Cystic Fibrosis

  Billings, J. L.

  Vertex Pharmaceuticals Incorporated

  6/1/19 → 7/31/21

  Project: Research project

• A Phase 2, Randomized, Double-blind Study Comparing Trem

  Patel, M. R.

  MedImmune, LLC

  6/1/13 → 6/30/18

  Project: Research project

• A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Tolerability, Biological Activity, and PK of ND L02 s0201 in Subjects with Idiopathic Pulmonary Fibrosis (IPF)

  Kim, H. J.

  NITTO DENKO TECH CORP

  10/2/18 → 1/1/22

  Project: Research project

• A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of VX-864 in PiZZ Subjects

  Reilkoff, R. A.

  Vertex Pharmaceuticals Incorporated

  9/21/20 → 9/21/21

  Project: Research project

• A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of NPC-21 for Kidney TransplantRecipients at High-Risk of Cytomegalovirus Infection, LionHeart21

  Young, J. H.

  NOBELPHARMA CO., LTD

  6/12/20 → 6/30/25

  Project: Research project

• A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of Abiraterone Acetate plus Prednisonewith or without Abemaciclib in Patients with Metastatic Castration-Resistant Prostate Cancer

  Rao, A.

  Eli Lilly and Company

  9/1/18 → 8/30/22

  Project: Research project

• A Phase 2, Randomized, Double-Blind, Placebo-Controlled,Parallel-Group, Multicenter, Dose Escalation and Proof-of-ConceptStudy to Evaluate the Safety and Efficacy of Razuprotafib inHospitalized Subjects With Moderate to Severe Coronavirus Disease

  Pritzker, M. R.

  AERPIO PHARMACEUTICALS, INC.

  7/1/20 → 7/31/24

  Project: Research project

• A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Clinical Study to Evaluate theEfficacy and Safety of Oral Inhalation of GB002 for the Treatment of WHO Group 1 Pulmonary ArterialHypertension (PAH)

  Thenappan, T.

  GB002, INC.

  1/1/21 → 1/31/25

  Project: Research project

• A Phase 2, Randomized, Double-Blind, Placebo-Controlled,

  Stewart, C.

  Hyperion Therapeutics

  7/20/09 → 10/26/11

  Project: Research project

• A Phase 2, Randomized, Double-Blind, Placebo-Controlled,

  Kim, H. J.

  Gilead Sciences, Inc.

  2/22/13 → 12/31/16

  Project: Research project

• A Phase 2, Randomized, Double-Blind, Placebo-Controlled

  Greeno, E. W.

  ASTELLAS PHARMA, INC.

  2/1/16 → 2/28/21

  Project: Research project

• A Phase 2, Randomized, Double-Blind, Placebo-Controlled

  Lake, J. R.

  Hyperion Therapeutics

  2/1/08 → 2/4/09

  Project: Research project

• A Phase 2, Randomized, Double-Blind, Placebo-Controlled

  Rheault, M. N.

  REGULUS THERAPEUTICS, INC.

  7/15/16 → 12/31/18

  Project: Research project

• A Phase 2, Randomized, Double-blind, Controlled Study to Evaluate the Safety and Efficacyof VX-121 Combination Therapy in Subjects Aged 18 Years and Older With Cystic Fibrosis

  Billings, J. L.

  Vertex Pharmaceuticals Incorporated

  3/21/19 → 1/1/21

  Project: Research project

• A Phase 2, Randmized, Multicenter, Placebo-Controlled, D

  Lake, J. R.

  EISAI MEDICAL RESEARCH INC.

  4/6/09 → 12/31/13

  Project: Research project

• A Phase 2, Pilot, Multicenter, Randomized, Placebo-Contr

  Hordinsky, M. K.

  Celgene Corporation

  3/1/12 → 2/28/14

  Project: Research project

• A Phase 2, Open-Label Study of the Safety and Efficacy o

  Bachanova, V.

  Incyte Corporation

  8/1/15 → 8/30/20

  Project: Research project

• A Phase 2, Open-Label Study of INCB050465 in Participants WithAutoimmune Hemolytic Anemia

  Vercellotti, G. M. & Mazepa, M.

  Incyte Corporation

  1/10/19 → 4/30/24

  Project: Research project

• A Phase 2, Open-Label Dose-Finding Study to Evaluate the

  Whitley, C. B.

  BIOMARIN PHARMACEUTICAL, INC.

  4/6/09 → 12/31/14

  Project: Research project

• A Phase 2, Open-Label, Switch-Over, Dose-Escalation Stud

  Berry, S. A.

  Hyperion Therapeutics

  2/5/07 → 8/29/09

  Project: Research project

• A Phase 2, Open-Label, Single-ArmStudy to Evaluate the Efficacy and Safety of Camidanlumab Tesirine (ADCT-301) in Patientswith Relapsed or Refractory Hodgkin Lymphoma

  Bachanova, V.

  ADC THERAPEUTICS SA

  7/16/19 → 7/31/24

  Project: Research project

• A Phase 2, Open-Label, Single-Arm Study to Evaluate the

  Geller, M. A.

  TESARO, INC.

  3/3/15 → 9/1/20

  Project: Research project

• A Phase 2, open-label, single-arm, intra-subject dose-es

  Lazaryan, A.

  Actelion Pharmaceuticals Ltd.

  5/1/15 → 4/30/19

  Project: Research project

• A Phase 2, Open-label, Randomized, Two-stage Clinical Studyof Alvocidib in Patients with Relapsed/Refractory AcuteMyeloid Leukemia Following Treatment with VenetoclaxCombination Therapy

  Warlick, E. D.

  TOLERO PHARMACEUTICALS, INC.

  3/1/20 → 2/28/25

  Project: Research project

• A Phase 2, Open-Label, Multiple-Dose Study to Evaluate the Safety,Tolerability, Pharmacokinetics, and Pharmacodynamics of NBI-74788 inPediatric Subjects with Congenital Adrenal Hyperplasia

  Sarafoglou, K. M.

  Neurocrine Biosciences, Inc.

  5/28/19 → 5/31/24

  Project: Research project

• A Phase 2, Open-label, Multinational Clinical Study to E

  Whitley, C. B.

  BIOMARIN PHARMACEUTICAL, INC.

  3/15/12 → 6/4/12

  Project: Research project

• A Phase 2, Open-Label, Multicenter Study of Single-Agent

  Bohjanen, K. A.

  Eli Lilly and Company

  10/14/08 → 12/31/11

  Project: Research project

• A Phase 2, Open-Label, Multi-Center, Randomized Trial to

  Lake, J. R.

  LIFECYCLE PHARMA

  9/10/08 → 2/10/12

  Project: Research project

• A Phase 2, Multiple-Dose, Dose-Escalation Study

  Sarafoglou, K. M.

  SPRUCE BIOSCIENCES, INC.

  5/1/17 → 5/30/22

  Project: Research project

• A Phase 2, Multicenter Study to Assess the Safety and Ef

  Domingo-Musibay, E.

  IOVANCE BIOTHERAPEUTICS

  5/1/17 → 5/30/22

  Project: Research project

• A Phase 2, Multi-Center ... Study to Assess Safety and I

  Hatsukami, D. K., Allen, S. S. & Jensen, J. A.

  NABI

  4/19/06 → 9/30/08

  Project: Research project

• A Phase 2, Multicenter,Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Risankizumab inAdult Subjects with Moderate to Severe Hidradenitis Suppurativa

  Goldfarb, N.

  ABBVIE INC.

  8/8/19 → 8/30/24

  Project: Research project

• A Phase 2, multicenter, randomized, placebo-controlled, doubleblind study in patients with acquired thrombotic thrombocytopenic purpura (aTTP) to evaluate the pharmacokinetics, safety, and efficacy of rADAMTS-13 (SHP655) administered in addition to stand

  Datta, Y. H. & Mazepa, M.

  Baxalta US Inc.

  7/1/19 → 7/30/24

  Project: Research project

• A Phase 2, Multi-Center, Randomized, Placebo-Controlled

  Billings, J. L.

  Seattle Children's Hospital

  9/1/13 → 6/30/18

  Project: Research project

• A Phase 2, Multi-Center, Randomized, Double-Blind, Place

  Billings, J. L.

  MPEX PHARMACEUTICALS, INC.

  9/1/08 → 8/31/10

  Project: Research project

• A phase 2, multi-center, randomized, double-blind, place

  Humar, A. & Kandaswamy, R.

  DOMPE S.P.A

  4/12/05 → 12/31/08

  Project: Research project

• A Phase 2, Multicenter, Randomized, Double-Blind, Parall

  Crow, S. J. & Peterson, C. B.

  Shire Development Inc.

  5/9/11 → 6/13/12

  Project: Research project

• A Phase 2, Multicenter, Randomized, Double-Blind, Contro

  Hordinsky, M. K.

  INTREPID THERAPEUTICS, INC.

  5/27/14 → 12/31/16

  Project: Research project